BROFAROMINE IN TREATMENT-RESISTANT DEPRESSED-PATIENTS - A COMPARATIVETRIAL VERSUS TRANYLCYPROMINE

In a controlled clinical inpatient trial (n = 93) comparing the effica cy and safety of brofaromine versus tranylcypromine for 6 weeks in tre atment-resistant major depressed patients, the two drugs were found to be of comparable afficacy and tolerability. The response rate (a 50% reduction) on the Hamilton Scale for Depression (HAMD) in both groups was about 73%. The most common side effects in the brofaromine group w ere sleep disorders, hypotension, tremor and dryness of mouth; and in the tranylcypromine group sleep disorders, fatigue, hypotension, tremo r and vertigo. Methodological and practical clinical implications of t he results are discussed.